Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43


Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance).

Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A.

Ther Adv Med Oncol. 2020 Mar 6;12:1758835920910913. doi: 10.1177/1758835920910913. eCollection 2020.


Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials.

Atkinson TM, Dueck AC, Satele DV, Thanarajasingam G, Lafky JM, Sloan JA, Basch E.

JAMA Oncol. 2019 Dec 26. doi: 10.1001/jamaoncol.2019.5566. [Epub ahead of print] No abstract available.


Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology.

Alliance Cancer in the Older Adult Committee:, Adjei A, Buckner JC, Cathcart-Rake E, Chen H, Cohen HJ, Dao D, De Luca JE, Feliciano J, Freedman RA, Goldberg RM, Hopkins J, Hubbard J, Jatoi A, Karuturi M, Kemeny M, Kimmick GG, Klepin HD, Krok-Schoen JL, Lafky JM, Le-Rademacher JG, Li D, Lichtman SM, Maggiore R, Mandelblatt J, Morrison VA, Muss HB, Ojelabi MO, Sedrak MS, Subbiah N, Sun V, Tuttle S, VanderWalde N, Wildes T, Wong ML, Woyach J.

J Geriatr Oncol. 2020 Mar;11(2):179-183. doi: 10.1016/j.jgo.2019.05.011. Epub 2019 Jun 11. No abstract available.


Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 Nov;33(11):2599-2609. doi: 10.1038/s41375-019-0477-x. Epub 2019 May 9.


Older-Patient-Specific Cancer Trials: A Pooled Analysis of 2,277 Patients (A151715).

Dao D, Zemla T, Jatoi A, Freedman RA, Hurria A, Muss H, Cohen HJ, Shulman LN, Citron M, Budman D, McMurray R, Partridge A, Carey L, Sedrak MS, Lafky JM, Le-Rademacher JG.

Oncologist. 2019 Jun;24(6):e284-e291. doi: 10.1634/theoncologist.2018-0803. Epub 2019 Apr 11.


Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101.

Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, Hurria A, Kimmick G, Le-Rademacher JG, Lichtman S, Muss HB, Shulman LN, Copur MS, Biggs D, Ramaswamy B, Lafky JM, Jatoi A.

Oncologist. 2019 May;24(5):617-623. doi: 10.1634/theoncologist.2018-0298. Epub 2018 Nov 8.


Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer.

Hurria A, Soto-Perez-de-Celis E, Allred JB, Cohen HJ, Arsenyan A, Ballman K, Le-Rademacher J, Jatoi A, Filo J, Mandelblatt J, Lafky JM, Kimmick G, Klepin HD, Freedman RA, Burstein H, Gralow J, Wolff AC, Magrinat G, Barginear M, Muss H.

J Am Geriatr Soc. 2019 May;67(5):920-927. doi: 10.1111/jgs.15493. Epub 2018 Aug 26.


Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study.

Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A.

Breast Cancer Res Treat. 2018 Sep;171(2):325-334. doi: 10.1007/s10549-018-4828-5. Epub 2018 May 22.


Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602).

Freedman RA, Dockter TJ, Lafky JM, Hurria A, Muss HJ, Cohen HJ, Jatoi A, Kemeny MM, Ruddy KJ.

Oncologist. 2018 Sep;23(9):1016-1023. doi: 10.1634/theoncologist.2018-0033. Epub 2018 Apr 19.


Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611).

Tallarico M, Foster JC, Seisler D, Lafky JM, Hurria A, Jatoi A, Cohen HJ, Muss HB, Bartlett N, Cheson BD, Jung SH, Leonard JP, Byrd JC, Nabhan C.

J Geriatr Oncol. 2018 Jul;9(4):321-328. doi: 10.1016/j.jgo.2018.03.018. Epub 2018 Apr 17.


The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance).

Gajra A, McCall L, Muss HB, Cohen HJ, Jatoi A, Ballman KV, Partridge AH, Sutton L, Parker BA, Magrinat G, Klepin HD, Lafky JM, Hurria A.

J Geriatr Oncol. 2018 May;9(3):221-227. doi: 10.1016/j.jgo.2018.02.003. Epub 2018 Mar 28.


The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Morrison VA, McCall L, Muss HB, Jatoi A, Cohen HJ, Cirrincione CT, Ligibel JA, Lafky JM, Hurria A.

J Geriatr Oncol. 2018 May;9(3):228-234. doi: 10.1016/j.jgo.2017.11.007. Epub 2017 Dec 8.


Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance).

Barton DL, Shuster LT, Dockter T, Atherton PJ, Thielen J, Birrell SN, Sood R, Griffin P, Terstriep SA, Mattar B, Lafky JM, Loprinzi CL.

Support Care Cancer. 2018 Apr;26(4):1335-1343. doi: 10.1007/s00520-017-3960-9. Epub 2017 Nov 21.


Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance).

Barton DL, Sloan JA, Shuster LT, Gill P, Griffin P, Flynn K, Terstriep SA, Rana FN, Dockter T, Atherton PJ, Tsai M, Sturtz K, Lafky JM, Riepl M, Thielen J, Loprinzi CL.

Support Care Cancer. 2018 Feb;26(2):643-650. doi: 10.1007/s00520-017-3878-2. Epub 2017 Sep 18.


Lymphedema, musculoskeletal events and arm function in older patients receiving adjuvant chemotherapy for breast cancer (Alliance A171302).

Hopkins JO, Allred J, Hurria A, Jatoi A, Lafky JM, Cohen H, Hudis C, Winer E, Mandelblatt J, Partridge A, Carey L, Muss HB.

Breast Cancer Res Treat. 2017 Dec;166(3):793-808. doi: 10.1007/s10549-017-4454-7. Epub 2017 Aug 20.


Comparative "nocebo effects" in older patients enrolled in cancer therapeutic trials: Observations from a 446-patient cohort.

Foster JC, Le-Rademacher JG, Feliciano JL, Gajra A, Seisler DK, DeMatteo R, Lafky JM, Hurria A, Muss HB, Cohen HJ, Jatoi A.

Cancer. 2017 Nov 1;123(21):4193-4198. doi: 10.1002/cncr.30867. Epub 2017 Jul 12.


A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I.

Pachman DR, Dockter T, Zekan PJ, Fruth B, Ruddy KJ, Ta LE, Lafky JM, Dentchev T, Le-Lindqwister NA, Sikov WM, Staff N, Beutler AS, Loprinzi CL.

Support Care Cancer. 2017 Nov;25(11):3407-3416. doi: 10.1007/s00520-017-3760-2. Epub 2017 May 27.


Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).

Kimmick GG, Major B, Clapp J, Sloan J, Pitcher B, Ballman K, Barginear M, Freedman RA, Artz A, Klepin HD, Lafky JM, Hopkins J, Winer E, Hudis C, Muss H, Cohen H, Jatoi A, Hurria A, Mandelblatt J.

Breast Cancer Res Treat. 2017 Jun;163(2):391-398. doi: 10.1007/s10549-017-4188-6. Epub 2017 Mar 10.


Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527.

Freedman RA, Foster JC, Seisler DK, Lafky JM, Muss HB, Cohen HJ, Mandelblatt J, Winer EP, Hudis CA, Partridge AH, Carey LA, Cirrincione C, Moreno-Aspitia A, Kimmick G, Jatoi A, Hurria A.

J Clin Oncol. 2017 Feb;35(4):421-431. doi: 10.1200/JCO.2016.69.4182. Epub 2016 Dec 19.


Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).

Freedman RA, Seisler DK, Foster JC, Sloan JA, Lafky JM, Kimmick GG, Hurria A, Cohen HJ, Winer EP, Hudis CA, Partridge AH, Carey LA, Jatoi A, Klepin HD, Citron M, Berry DA, Shulman LN, Buzdar AU, Suman VJ, Muss HB.

Breast Cancer Res Treat. 2017 Jan;161(2):363-373. doi: 10.1007/s10549-016-4051-1. Epub 2016 Nov 19.


Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505).

Pachman DR, Qin R, Seisler D, Smith EM, Kaggal S, Novotny P, Ruddy KJ, Lafky JM, Ta LE, Beutler AS, Wagner-Johnston ND, Staff NP, Grothey A, Dougherty PM, Cavaletti G, Loprinzi CL.

Support Care Cancer. 2016 Dec;24(12):5059-5068. Epub 2016 Aug 18.


Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, Dietrich L, Biggs D, Lafky JM, Loprinzi CL.

N Engl J Med. 2016 Jul 14;375(2):134-42. doi: 10.1056/NEJMoa1515725.


Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.

Majithia N, Atherton PJ, Lafky JM, Wagner-Johnston N, Olson J, Dakhil SR, Perez EA, Loprinzi CL, Hines SL.

Support Care Cancer. 2016 Mar;24(3):1219-26. doi: 10.1007/s00520-015-2915-2. Epub 2015 Aug 23.


Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance).

Pachman DR, Qin R, Seisler DK, Smith EM, Beutler AS, Ta LE, Lafky JM, Wagner-Johnston ND, Ruddy KJ, Dakhil S, Staff NP, Grothey A, Loprinzi CL.

J Clin Oncol. 2015 Oct 20;33(30):3416-22. doi: 10.1200/JCO.2014.58.8533. Epub 2015 Aug 17.


MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy.

Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi CL.

Support Care Cancer. 2016 Mar;24(3):1071-8. doi: 10.1007/s00520-015-2876-5. Epub 2015 Aug 8.


5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.

Wagner-Johnston ND, Sloan JA, Liu H, Kearns AE, Hines SL, Puttabasavaiah S, Dakhil SR, Lafky JM, Perez EA, Loprinzi CL.

Cancer. 2015 Aug 1;121(15):2537-43. doi: 10.1002/cncr.29327. Epub 2015 Apr 30.


Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.

Galanis E, Anderson SK, Lafky JM, Uhm JH, Giannini C, Kumar SK, Kimlinger TK, Northfelt DW, Flynn PJ, Jaeckle KA, Kaufmann TJ, Buckner JC.

Clin Cancer Res. 2013 Sep 1;19(17):4816-23. doi: 10.1158/1078-0432.CCR-13-0708. Epub 2013 Jul 5.


Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831.

Moreno-Aspitia A, Hillman DW, Dyar SH, Tenner KS, Gralow J, Kaufman PA, Davidson NE, Lafky JM, Reinholz MM, Lingle WL, Kutteh LA, Carney WP, Dueck AC, Perez EA.

Cancer. 2013 Aug 1;119(15):2675-82. doi: 10.1002/cncr.28130. Epub 2013 Jun 6.


Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Cosentino-Boehm AL, Lafky JM, Greenwood TM, Kimbler KD, Buenafe MC, Wang Y, Branscum AJ, Yang P, Maihle NJ, Baron AT.

Diagnostics (Basel). 2013 Jan 14;3(1):13-32. doi: 10.3390/diagnostics3010013.


Soluble epidermal growth factor receptor: a biomarker of epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Cora EM, Buenafe MC, Liu D, Rademaker A, Fishman DA, Podratz KC, Reiter JL, Maihle NJ.

Cancer Treat Res. 2009;149:189-202. doi: 10.1007/978-0-387-98094-2_9. Review. No abstract available.


Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

Lafky JM, Wilken JA, Baron AT, Maihle NJ.

Biochim Biophys Acta. 2008 Apr;1785(2):232-65. doi: 10.1016/j.bbcan.2008.01.001. Epub 2008 Feb 7. Review.


Soluble epidermal growth factor receptor acridinium-linked immunosorbent assay.

Lafky JM, Baron AT, Maihle NJ.

Methods Mol Biol. 2006;327:39-47.


The granulin-epithelin precursor is a steroid-regulated growth factor in endometrial cancer.

Jones MB, Houwink AP, Freeman BK, Greenwood TM, Lafky JM, Lingle WL, Berchuck A, Maxwell GL, Podratz KC, Maihle NJ.

J Soc Gynecol Investig. 2006 May;13(4):304-11.


Serum soluble epidermal growth factor receptor concentrations decrease in postmenopausal metastatic breast cancer patients treated with letrozole.

Lafky JM, Baron AT, Cora EM, Hillman DW, Suman VJ, Perez EA, Ingle JN, Maihle NJ.

Cancer Res. 2005 Apr 15;65(8):3059-62.


Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.

Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):306-18. Erratum in: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583.


Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer.

Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13.


A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.

Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN.

Ann Oncol. 2002 Aug;13(8):1225-35.


Receptor tails and transcriptional regulation.

Maihle NJ, Lafky JM.

Trends Cell Biol. 2002 Apr;12(4):160-1. No abstract available.


EGF/ErbB receptor family in ovarian cancer.

Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC.

Cancer Treat Res. 2002;107:247-58. Review.


A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women.

Baron AT, Lafky JM, Suman VJ, Hillman DW, Buenafe MC, Boardman CH, Podratz KC, Perez EA, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1175-85.


Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer.

Baron AT, Lafky JM, Boardman CH, Balasubramaniam S, Suman VJ, Podratz KC, Maihle NJ.

Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37.


A sandwich type acridinium-linked immunosorbent assay (ALISA) detects soluble ErbB1 (sErbB1) in normal human sera.

Baron AT, Lafky JM, Connolly DC, Peoples J, O'Kane DJ, Suman VJ, Boardman CH, Podratz KC, Maihle NJ.

J Immunol Methods. 1998 Oct 1;219(1-2):23-43.


Monoclonal antibodies specific for peptide epitopes of the epidermal growth factor receptor's extracellular domain.

Baron AT, Huntley BK, Lafky JM, Reiter JL, Liebenow J, McCormick DJ, Ziesmer SC, Roche PC, Maihle NJ.

Hybridoma. 1997 Jun;16(3):259-71.


Supplemental Content

Loading ...
Support Center